Overview

Atazanavir Twice Daily

Status:
Completed

Trial end date:
2006-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this clinical research study is to assess the pharmacokinetics of atazanavir administered twice-daily relative to historical data from atazanavir/ritonavir 300/100 mg, given once daily.

Phase:

Phase 1

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

Atazanavir Sulfate